ClinicalTrials.gg

Program

flonoltinib maleate

Also written as “Flonoltinib Maleate” and “Flonoltinib Maleate Tablets”.

Its studies are led by Chengdu Zenitar Biomedical Technology.

Furthest: phase 2, since Dec 19, 20252 company-led studies, 1 open or runningNext primary completion: Dec 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chengdu Zenitar Biomedical Technology21 open or runningphase 2since Dec 19, 2025Mar 6, 2024Dec 30, 2027phase 2 · NCT07443306

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2024First study: phase 1 study in Heathly SubjectsFirst studyNCT06387966 · 40 enrolled · China
  2. Dec 19, 2025Phase 2 study in MFPhase 2 reachedNCT07443306 · 64 planned · China

Ahead

  1. Dec 30, 2027Primary completion: phase 2 study in MFNCT07443306

TargetBeta

FLT3 →JAK2 →read by rule
“The maleate salt form of flonoltinib, an orally bioavailable dual inhibitor of both Janus-associated kinase 2 (JAK2) and of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
jaktinibruleSuzhou Zelgen Biopharmaceuticalsphase 331
pacritinibruleSwedish Orphan Biovitrumphase 318
flonoltinibruleChengdu Zenitar Biomedical Technologyphase 37

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07443306MF · China2RecruitingDec 30, 202764
NCT06387966Heathly Subjects · China1CompletedAug 15, 202440

How it is read

Names in the registry

  • “Flonoltinib Maleate”, 1 entry
  • “Flonoltinib Maleate Tablets”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.